No profile data available.
Marker Therapeutics, Inc. (MRKR) is a healthcare company in the blood cancer treatment drugs industry, based in Houston, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$12.16 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $16.20 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
Marker Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $6.59 million in fiscal year 2024. In Q2 2026 revenue was $0.
$16.20 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Lite Strategy, Inc. (LITS), Actinium Pharmaceuticals, Inc. (ATNM), Estrella Immunopharma, Inc. (ESLA), Karyopharm Therapeutics Inc. (KPTI).